The U.S. Food and Drug Administration’s staff reviewers said on Tuesday the safety data for Pfizer Inc.’s experimental respiratory syncytial virus (RSV) vaccine in pregnant women was “generally favorable”.
Moderna Inc. on Thursday reported a surprise profit and stronger-than-expected sales for its COVID-19 vaccine in the first quarter, as it received payments for orders that were deferred last year.
The U.S. Food and Drug Administration has approved GSK Plc’s respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
GSK Chief Executive Emma Walmsley on Wednesday made replenishing the drugmaker’s pipeline of vaccines and therapies her number-one priority. But analysts were disappointed she did not give more details on how she and her management team plan to find the company’s next set of blockbuster drugs.
Pfizer Inc. said on Wednesday the U.S. Food and Drug Administration will review its respiratory syncytial virus (RSV) vaccine candidate on priority.
As it gears up to launch several new products in the coming months, Moderna has created a new leadership role and onboarded an industry veteran, the company announced Thursday.
Pfizer is leveraging its funding and experience with vaccines for meningococcal, flu and RSV to further expand its presence in the field.